← Back to list
08.02.42a, Penpulimab-kcqx
Act
by Jun 1, 2026
Effective date
Jun 1, 2026
Identified
Jun 19, 2026
Summary
Independence Blue Cross expanded Penpulimab-kcqx coverage effective June 1, 2026 to include three new cancer indications (anal carcinoma, appendiceal cancers, small bowel adenocarcinoma) and revised head and neck cancer criteria, adding 12 new ICD-10 diagnosis codes. Billing teams must update systems to recognize these new diagnosis codes and apply the specific medical necessity criteria for coverage determinations.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
by Jun 1, 2026 · 4 steps
01Billing team must update billing software and eligibility verification systems to recognize the 12 new ICD-10 diagnosis codes (C17.0, C17.1, C17.2, C17.3, C17.8, C17.9, C18.1, C21.0, C21.1, C21.2, C21.8, C31.0, C31.1, D37.3) for Penpulimab-kcqx coverage under Independence Blue Cross commercial plans.
02Configure the system to require prior authorization verification against the new medical necessity criteria for anal carcinoma (combination therapy or single-agent second-line), appendiceal cancers (dMMR/MSI-H or POLE/POLD1 mutations, no prior checkpoint inhibitor), and revised nasopharyngeal carcinoma criteria.
03Update encounter templates and prior auth request forms to prompt providers to document required clinical criteria (ECOG performance status, disease stage, mutation status where applicable).
04Train billing and prior authorization staff on the new indications and their specific coverage requirements.
If missed: Failure to apply the updated criteria may result in claim denials for services that do not meet the specified medical necessity thresholds.
Codes mentioned
C17.0C17.1C17.2C17.3C17.8C17.9C18.1C21.0C21.1C21.2C21.8C31.0C31.1D37.3C9399J3590
Original notice
08.02.42a, Penpulimab-kcqx
medpolicy.ibx.com · Always check the source before changing claims.
Related changes
See all Independence Blue Cross changes →MA08.186a, Penpulimab-kcqxMediumEffective Jun 1, 2026 · Pharmacy08.02.42b, Penpulimab-kcqxLowEffective Oct 1, 2026 · PharmacyMA08.186, Penpulimab-kcqxMediumEffective Dec 29, 2025 · PharmacyMA08.184a, Cosibelimab-ipdl (Unloxcyt™)MediumEffective Jun 1, 2026 · PharmacyBrowse every Independence Blue Cross change in the policy list